Quick Answer
BridgeBio Pharma, Inc. reported Cash and Equivalents of $570.12 million for fiscal year 2025.
BridgeBio Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $570.12M | -16.3% |
| 2024 | $681.10M | +81.2% |
| 2023 | $375.94M | -0.2% |
| 2022 | $376.69M | -4.3% |
| 2021 | $393.77M | +10.6% |
| 2020 | $356.08M | -2.1% |
| 2019 | $363.77M | -16.6% |
| 2018 | $436.09M | +374.0% |
| 2017 | $92.00M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $642.95M | +141.4% | -14.2% |
| June 30, 2025 | $748.95M | +83.6% | +38.5% |
| March 31, 2025 | $540.60M | +13.8% | -20.6% |
| December 31, 2024 | $681.10M | +81.2% | +155.7% |
| September 30, 2024 | $266.32M | -47.3% | -34.7% |
| June 30, 2024 | $407.96M | +34.9% | -14.2% |
| March 31, 2024 | $475.22M | +16.7% | +26.4% |
| December 31, 2023 | $375.94M | -0.2% | -25.6% |
- BridgeBio Pharma, Inc. showed a decrease of -16.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, BridgeBio Pharma, Inc.’s cash and equivalents has grown by 519.7% (from $92.00 million to $570.12 million).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: